MX359664B - Tratamiento de cáncer de mama. - Google Patents
Tratamiento de cáncer de mama.Info
- Publication number
- MX359664B MX359664B MX2014001218A MX2014001218A MX359664B MX 359664 B MX359664 B MX 359664B MX 2014001218 A MX2014001218 A MX 2014001218A MX 2014001218 A MX2014001218 A MX 2014001218A MX 359664 B MX359664 B MX 359664B
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- treatment
- compounds
- iii
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición acondicionadora que comprende desde 0.4 a 8% en peso de alcohol graso teniendo desde 8-22 carbonos, desde 0.1 a 2% en peso de componente de surfactante catiónico, agua y en donde la composición tiene una Masa de arrastre desde 1 a 250 g.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161513361P | 2011-07-29 | 2011-07-29 | |
PCT/US2012/048471 WO2013066440A1 (en) | 2011-07-29 | 2012-07-27 | Treatment of breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014001218A MX2014001218A (es) | 2014-08-22 |
MX359664B true MX359664B (es) | 2018-10-05 |
Family
ID=48192564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014001218A MX359664B (es) | 2011-07-29 | 2012-07-27 | Tratamiento de cáncer de mama. |
Country Status (18)
Country | Link |
---|---|
US (4) | US9517229B2 (es) |
EP (4) | EP3430907A1 (es) |
JP (2) | JP6158180B2 (es) |
KR (1) | KR101923250B1 (es) |
CN (1) | CN103997894B (es) |
BR (1) | BR112014002200A2 (es) |
CA (1) | CA2843417C (es) |
CY (1) | CY1121038T1 (es) |
DK (1) | DK2739153T3 (es) |
EA (1) | EA028452B1 (es) |
ES (1) | ES2696074T3 (es) |
HK (2) | HK1198867A1 (es) |
HU (1) | HUE040524T2 (es) |
MX (1) | MX359664B (es) |
PL (1) | PL2739153T3 (es) |
PT (1) | PT2739153T (es) |
SI (1) | SI2739153T1 (es) |
WO (1) | WO2013066440A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3430907A1 (en) * | 2011-07-29 | 2019-01-23 | Medivation Prostate Therapeutics LLC | Treatment of breast cancer |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
UA115805C2 (uk) | 2013-04-17 | 2017-12-26 | Сігнал Фармасьютікалз, Елелсі | Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати |
JP6945587B2 (ja) * | 2013-11-07 | 2021-10-06 | デシフェラ ファーマシューティカルズ,エルエルシー | ガンの処置に有用なtie2キナーゼの阻害方法 |
EP3065549A4 (en) * | 2013-11-07 | 2017-05-24 | Deciphera Pharmaceuticals, LLC | Methods for inhibiting tie2 kinase useful in the treatment of cancer |
JP6648040B2 (ja) | 2014-05-28 | 2020-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用 |
EP3604556A1 (en) | 2014-12-12 | 2020-02-05 | Medivation Prostate Therapeutics LLC | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
CN107530291A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 双重负载的脂质体药物制剂 |
CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
US9963433B2 (en) * | 2016-01-29 | 2018-05-08 | Wayne State University | Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor |
EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
CN107987055A (zh) * | 2017-12-19 | 2018-05-04 | 刘秀云 | 硫代咪唑二酮类雄激素受体拮抗剂及其用途 |
SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
WO2020113088A1 (en) * | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
BR112022002609A2 (pt) | 2019-08-12 | 2022-08-09 | Deciphera Pharmaceuticals Llc | Métodos de tratamento de tumores estromais gastrointestinais |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
CA3188358A1 (en) * | 2020-08-03 | 2022-02-10 | Robert Scott SEITZ | Classifying tumors and predicting responsiveness |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
PT2444085E (pt) | 2005-05-13 | 2015-06-11 | Univ California | Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro |
CA2630974A1 (en) | 2005-11-23 | 2007-05-31 | University Of Utah Research Foundation | Methods and compositions involving intrinsic genes |
PL2656841T3 (pl) * | 2006-03-27 | 2017-01-31 | The Regents Of The University Of California | Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym |
EP2439196A1 (en) | 2006-03-29 | 2012-04-11 | The Regents of The University of California | Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder |
EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
WO2009114534A1 (en) * | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
WO2009158143A1 (en) | 2008-05-30 | 2009-12-30 | The University Of North Carolina At Chapel Hill | Gene expression profiles to predict breast cancer outcomes |
AU2010218052A1 (en) | 2009-02-24 | 2011-09-08 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
WO2010118354A1 (en) | 2009-04-09 | 2010-10-14 | Medivation Prostate Therapeutics, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof |
US8507195B2 (en) * | 2009-08-20 | 2013-08-13 | The Regents Of The University Of Colorado | MiRNAs dysregulated in triple-negative breast cancer |
WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
US9066963B2 (en) | 2011-03-15 | 2015-06-30 | The University Of North Carolina At Chapel Hill | Methods of treating breast cancer with anthracycline therapy |
EP3430907A1 (en) * | 2011-07-29 | 2019-01-23 | Medivation Prostate Therapeutics LLC | Treatment of breast cancer |
AU2012345789B2 (en) | 2011-11-30 | 2018-02-15 | British Columbia Cancer Agency Branch | Methods of treating breast cancer with taxane therapy |
JP6153613B2 (ja) | 2012-08-23 | 2017-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレート | 乳がん治療を決定する方法 |
US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
WO2014075067A1 (en) | 2012-11-12 | 2014-05-15 | Nanostring Technologies, Inc. | Methods to predict breast cancer outcome |
US10679730B2 (en) | 2013-05-28 | 2020-06-09 | The University Of Chicago | Prognostic and predictive breast cancer signature |
EP3604556A1 (en) | 2014-12-12 | 2020-02-05 | Medivation Prostate Therapeutics LLC | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
-
2012
- 2012-07-27 EP EP18190012.7A patent/EP3430907A1/en not_active Withdrawn
- 2012-07-27 PT PT12846720T patent/PT2739153T/pt unknown
- 2012-07-27 BR BR112014002200A patent/BR112014002200A2/pt not_active Application Discontinuation
- 2012-07-27 ES ES12846720T patent/ES2696074T3/es active Active
- 2012-07-27 DK DK12846720.6T patent/DK2739153T3/en active
- 2012-07-27 CN CN201280048192.2A patent/CN103997894B/zh active Active
- 2012-07-27 US US14/236,036 patent/US9517229B2/en active Active
- 2012-07-27 SI SI201231453T patent/SI2739153T1/sl unknown
- 2012-07-27 CA CA2843417A patent/CA2843417C/en active Active
- 2012-07-27 KR KR1020147005617A patent/KR101923250B1/ko active IP Right Grant
- 2012-07-27 WO PCT/US2012/048471 patent/WO2013066440A1/en active Application Filing
- 2012-07-27 EP EP19187649.9A patent/EP3610731A1/en not_active Withdrawn
- 2012-07-27 EA EA201400178A patent/EA028452B1/ru not_active IP Right Cessation
- 2012-07-27 EP EP12846720.6A patent/EP2739153B1/en active Active
- 2012-07-27 PL PL12846720T patent/PL2739153T3/pl unknown
- 2012-07-27 JP JP2014523048A patent/JP6158180B2/ja active Active
- 2012-07-27 HU HUE12846720A patent/HUE040524T2/hu unknown
- 2012-07-27 EP EP20191500.6A patent/EP3791724A1/en not_active Withdrawn
- 2012-07-27 MX MX2014001218A patent/MX359664B/es active IP Right Grant
-
2014
- 2014-12-10 HK HK14112422.7A patent/HK1198867A1/xx unknown
-
2015
- 2015-02-11 HK HK15101529.1A patent/HK1201413A1/xx unknown
-
2016
- 2016-12-09 US US15/373,914 patent/US10111861B2/en active Active
-
2017
- 2017-03-31 JP JP2017072819A patent/JP2017141269A/ja active Pending
-
2018
- 2018-10-24 US US16/168,896 patent/US20190262315A1/en not_active Abandoned
- 2018-11-08 CY CY181101174T patent/CY1121038T1/el unknown
-
2020
- 2020-01-22 US US16/749,133 patent/US20210069154A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014001218A (es) | Tratamiento de cancer de mama. | |
PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MA40076A (fr) | Inhibiteurs de syk | |
DOP2015000083A (es) | Modulación de la expresión de receptores androgénicos | |
IN2015DN03795A (es) | ||
MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
MX2013008212A (es) | Derivados de 7-azaindol. | |
NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
MX364486B (es) | Derivados de piridazinona-amidas. | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
IN2015DN00438A (es) | ||
MX2017006015A (es) | Composiciones para usar en el tratamiento de cancer renal. | |
PH12015501088A1 (en) | Dimeric compounds | |
MX2019010098A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
MX2013007268A (es) | Activadores de pkm2 bicíclicos. | |
MX365392B (es) | Composición de combinación de pac-1 y doxorrubicina. | |
MX2015001551A (es) | Compuestos y composiciones activadoras de enzima. | |
MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
SG10201900564WA (en) | Methods for treating cancer | |
MX2016008042A (es) | Derivados de imidazopirazinona. | |
WO2014110163A3 (en) | Melk regulation for the treatment of breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: ARESCO TECHNOLOGIES, LLC |
|
FG | Grant or registration |